Kanabo Group (LSE:KNB) EBIT: £-8.28 Mil (TTM As of Jun. 2024)


What is Kanabo Group EBIT?

Kanabo Group LSE:KNB EBIT is £-8.28 Mil as of Jun. 2024.

Kanabo Group's earnings before interest and taxes (EBIT) for the six months ended in Jun. 2024 was £-1.70 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2024 was £-8.28 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Kanabo Group's annualized ROC % for the quarter that ended in Jun. 2024 was -62.66%. Kanabo Group's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was -581.82%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Kanabo Group's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was -9,743.53%.


Kanabo Group  (LSE:KNB) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Kanabo Group's annualized ROC % for the quarter that ended in Jun. 2024 is calculated as:

ROC % (Q: Jun. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Jun. 2024 ))/ count )
=-3.468 * ( 1 - 0% )/( (6.499 + 4.571)/ 2 )
=-3.468/5.535
=-62.66 %

where

Note: The Operating Income data used here is two times the semi-annual (Jun. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Kanabo Group's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Jun. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Jun. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-3.392/( ( (0.049 + max(1.081, 0)) + (0.036 + max(-0.143, 0)) )/ 2 )
=-3.392/( ( 1.13 + 0.036 )/ 2 )
=-3.392/0.583
=-581.82 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.02 + 0.056 + 1.582) - (0.171 + 0 + 0.406)
=1.081

Working Capital(Q: Jun. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.01 + 0.052 + 0.542) - (0.747 + 0 + 0)
=-0.143

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Kanabo Group's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Jun. 2024 )
=-8.282/0.085
=-9,743.53 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kanabo Group EBIT Related Terms


Kanabo Group EBIT Historical Data

* Premium members only.

The historical data trend for Kanabo Group's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kanabo Group EBIT Chart

Kanabo Group Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial -0.36 -0.56 -4.55 -6.81 -7.95

Kanabo Group Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.32 -3.49 -1.36 -6.59 -1.70

LSE:KNB vs HCA, THC, EHC: EBIT Comparison

For the Medical Care Facilities subindustry, Kanabo Group's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kanabo Group EV-to-EBIT vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Kanabo Group's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Kanabo Group's EV-to-EBIT falls into.



Kanabo Group EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was £-8.28 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of £-8.28 Mil mean?
Kanabo Group (LSE:KNB) has a EBIT of £-8.28 Mil as of Jun. 2024. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Kanabo Group.
Is Kanabo Group's EBIT too high?
Kanabo Group's current EBIT is £-8.28 Mil.
How does Kanabo Group's EBIT compare to HCA and THC?
Kanabo Group's EBIT of £-8.28 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Healthcare Providers & Services company?
A good EBIT depends on the Healthcare Providers & Services industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Kanabo Group. Kanabo Group's current EBIT is £-8.28 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kanabo Group stock overvalued right now?
Kanabo Group (LSE:KNB) has a current EBIT of £-8.28 Mil. The current EBIT is £-8.28 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Kanabo Group (LSE:KNB), the current EBIT is £-8.28 Mil as of Jun. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kanabo Group Business Description

Address 137-139 Brent Street, Churchill House, London, GBR, NW4 4DJ
Kanabo Group PLC is a research and development company engaged in selling a range of THC-Free retail CBD products in the markets and it is in the process of developing medical cannabis products. Its reportable segments include Primary Care and Secondary Care. The Primary Care segment, which derives key revenue, includes Tele pharma services provided by GPS and The Secondary Care segment includes the development and distribution of cannabis-derived medical and wellness products. Geographically company has a presence in the United Kingdom and Israel.